Comprehensive Guide to Psychotropic Drugs for Children and Adolescents

Get quick and comprehensive information on psychotropic drugs specifically designed for children and adolescents. Accurate, up-to-date, and packed with user-friendly comparison charts and tables, this handbook is an essential reference for mental health professionals.

A Standard Reference for Mental Health Professionals

The Clinical Handbook of Psychotropic Drugs for Children and Adolescents has become a go-to resource for psychiatrists, pediatricians, psychologists, physicians, pharmacists, nurses, and other mental health professionals. This trusted guide provides easy-to-read comparison charts and tables for a quick overview of treatment options, including dosages, side effects, pharmacokinetics, and interactions.

Key Features:

• Succinct, bulleted information on all classes of medication, including on- and off-label indications, side effects, interactions, pharmacodynamics, and nursing implications.
• Potential interactions and side effects summarized in comparison charts for easy reference.
• Instantly recognizable icons and full-color design throughout, making it easy to find the information you need at a glance.
• Clearly written patient and caregiver information sheets available for download as printable PDF files.

New in This Edition:

• New chapters on Prescribing Safely and Ethically to Children and Adolescents, Pharmacogenetic Information for Common Psychotropic Drugs, and Aggression Management in Children and Adolescents.
• Neuroscience-based nomenclature added to Product Availability tables for enhanced clarity.
• Antipsychotic-Induced Extrapyramidal Side Effect (EPSE) completely revised, plus a new section on monitoring scales for EPSE.
• Anxiolytics section on buspirone and benzodiazepine comparison table revised for improved accuracy.
• Mood Stabilizers chapter extensively revised to reflect the latest research and developments.
• Natural Health Products comprehensively revised for a more comprehensive understanding.
• New Unapproved Treatments revised, including preliminary evidence for cannabidiol and folinic acid for autism spectrum disorder and ketamine for mood disorder.
• New agents include deutetrabenazine, ethopropazine, lemborexant, lumateperone, orphenadrine, tetrabenazine, valbenazine, and viloxazine.
• New formulations and trade names include Austedo, Caplyta, Dayvigo, Drizalma Sprinkle, Elepsia XR, Eprontia, Evekeo ODT, Gocovri, Hetlioz LQ, Ingrezza, Invega Hafyera, Jornay PM, Loreev XR, Lybalvi, Osmolex ER, Oxtellar XR, Parsitan, Perseris, Qelbree, Qudexy XR, Secuado, Spritam, Tyrvaya, and Valtoco.

Product Details:

• Publisher: HOGRE
• Edition: 5th edition (May 8, 2023)
• Language: English
• Format: Spiral-bound
• Pages: 438
• ISBN-10: 0889376255
• ISBN-13: 978-0889376250